Tiny Molecule Controls Stress-Induced Heart Disease
News Mar 23, 2007
A tiny snippet of RNA, a chemical cousin of DNA, controls damage to the heart under several types of stress, researchers at UT Southwestern Medical Center have found.
The published discovery, appeared online on Science Express and in a later edition of Science magazine, could mean that blocking the small molecule might become a way to prevent or treat heart damage, the scientists say.
“We’ve discovered a new and completely unanticipated mechanism for regulating the contractility of the heart,” said Dr. Eric Olson, chairman of molecular biology and senior author of the study. “We’re very excited about the therapeutic implications, but we still have much work left to do.”
Dr. Olson is director of the Nancy B. and Jake L. Hamon Center for Basic Research in Cancer and the Nearburg Family Center for Basic Research in Pediatric Oncology.
When adult heart cells contract, they use two forms of a protein called myosin. One form, called alpha-myosin heavy chain, is fast and efficient, while beta-myosin heavy chain is slower and less efficient. When the heart is damaged, the amount of alpha-myosin decreases and the proportion of beta-myosin increase.
The research focused on a small RNA molecule – called a microRNA – named miR-208, which occurs almost exclusively in heart muscle. The molecule is made by a portion of the gene that codes for the alpha-myosin protein.
“We speculated that it had an important function, since it was located in such an important gene,” said Dr. Eva van Rooij, a postdoctoral researcher in molecular biology and the study’s lead author.
The scientists genetically engineered a group of mice so they couldn’t produce miR-208. The mice were then subjected to conditions that would normally damage the heart and increase the amount of beta-myosin. Those conditions included hypothyroidism, treatment with a protein that causes heart enlargement and failure, and increasing how hard the heart had to pump.
In mice that had miR-208 present at normal levels, heart damage occurred. But in the animals lacking miR-208, the heart remained healthier, at least in the short term, and levels of beta-myosin remained low.
The researchers also engineered mice to express three times the normal level of miR-208, and found that they had elevated levels of beta-myosin. Work is currently under way to see if those mice show heart damage. MiR-208 is identical in humans, mice and other animals, indicating that it has a basic and widespread function in controlling heart damage, Dr. Olson said.
The work suggests that if miR-208 can be tied up or eliminated by therapeutic treatment, it might be a way to treat heart disease, Dr. van Rooij said. “That would be golden, because even a tiny increase in beta-myosin heavy chain in humans has been proven to diminish heart function,” she said.
Although miR-208 appears to damage the heart during stress, it may have beneficial functions for maintaining normal action of heart muscle cells, Dr. Olson said. So any therapeutic approach would probably need to target its harmful stress responses while leaving normal function alone, he said.
Other UT Southwestern researchers involved in the study were Lillian Sutherland and Xiaoxia Qi, both research scientists in molecular biology; Dr. James Richardson, professor of pathology and molecular biology; and Dr. Joseph Hill, associate professor of internal medicine.
The work was supported by the National Institutes of Health and the Donald W. Reynolds Cardiovascular Clinical Research Center at UT Southwestern.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.